small molecule

MEKINIST

TRAMETINIB DIMETHYL SULFOXIDE

Loss of exclusivityFebruary 2034latest FDA-listed patent expiry
CompanyNovartisView the full company profile on CliffBio

Drug detail

Brand nameMEKINIST
Active ingredientTRAMETINIB DIMETHYL SULFOXIDE
StrengthEQ 2MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2013
Marketing statusRX

Listed patents

PatentExpiresType
10869869*PEDFebruary 2034
10869869August 2033use U-3184
9271941*PEDJuly 2032
9155706*PEDJuly 2032
8580304*PEDJuly 2032
9399021*PEDJuly 2032
8580304January 2032product
9271941January 2032product
9399021January 2032product
9155706January 2032product
8703781*PEDApril 2031
8952018*PEDApril 2031
8703781October 2030substance, product
8952018October 2030use U-2020
7378423*PEDNovember 2027
7378423May 2027substance, product

Regulatory exclusivity

CodeExpires
PEDSeptember 2030
ODE-428March 2030
PEDSeptember 2026
I-908March 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MEKINIST patent cliff — loss of exclusivity February 2034 | CliffBio